Exploring Dermata Therapeutics, Inc. (DRMA) Investor Profile: Who’s Buying and Why?

As Dermata Therapeutics, Inc. (DRMA) navigates the complex world of medical dermatology, have you ever wondered who is investing in this company and, more importantly, why? With a 52-week low of $0.70 and a high of $6.17, and a recent closing price of $0.7072 on April 21, 2025, DRMA presents an intriguing case for investors. Is it the potential of XYNGARI™, their lead product candidate in Phase 3 clinical trials for acne, or perhaps the promise of DMT410 for treating hyperhidrosis that's capturing attention? Institutional ownership stands at 54,003 shares, with major players like Armistice Capital, Llc holding significant positions. But with analysts predicting a potential surge to $6.00, a staggering 745.07% upside, is now the time to delve deeper into DRMA's investor profile?

Dermata Therapeutics, Inc. (DRMA) Who Invests in Dermata Therapeutics, Inc. (DRMA) and Why?

Understanding the investor profile of Dermata Therapeutics, Inc. (DRMA) involves examining the various types of investors, their motivations, and the strategies they employ. This insight is crucial for current and prospective investors, as well as for the company itself, to gauge market sentiment and long-term stability. Dermata Therapeutics, Inc. (DRMA) is a late-stage biotechnology company focused on identifying, developing, and commercializing innovative, differentiated, and proprietary medical dermatology products. Therefore, its investor base is likely influenced by factors specific to the biotech industry, such as clinical trial results, regulatory approvals, and market potential of its products.

Key Investor Types:

The investor base of Dermata Therapeutics, Inc. (DRMA) can be categorized into several key types:

• Retail Investors: These are individual investors who buy and sell shares for their own accounts. They may be attracted to Dermata Therapeutics, Inc. (DRMA) due to its potential for growth in the medical dermatology sector.
• Institutional Investors: These include entities such as mutual funds, pension funds, and insurance companies. Institutional investors often have a longer-term investment horizon and conduct thorough due diligence before investing.
• Hedge Funds: These are investment partnerships that use more aggressive strategies, such as short-selling and leverage, to generate returns. Hedge funds may invest in Dermata Therapeutics, Inc. (DRMA) based on specific market opportunities or perceived mispricing of the stock.
• Venture Capital and Private Equity: Given Dermata Therapeutics, Inc. (DRMA)'s stage as a development-focused biotech company, venture capital and private equity firms may have been early investors, providing capital to fund research and development.

Investment Motivations:

Investors are drawn to Dermata Therapeutics, Inc. (DRMA) for a variety of reasons, often linked to the company's unique position and potential in the market:

• Growth Prospects: The primary motivation for many investors is the potential for significant capital appreciation. Positive clinical trial outcomes and successful commercialization of its dermatology products can drive substantial growth.
• Market Position: Dermata Therapeutics, Inc. (DRMA)'s focus on innovative and differentiated products in medical dermatology can provide a competitive edge, attracting investors looking for companies with strong market positions.
• Innovation and Technology: Investors are often attracted to companies with innovative technologies and unique approaches to addressing unmet medical needs. Dermata Therapeutics, Inc. (DRMA)'s proprietary products and focus on medical dermatology make it an attractive option for those seeking exposure to cutting-edge biotech innovation.

Investment Strategies:

The investment strategies employed by Dermata Therapeutics, Inc. (DRMA) investors can vary widely, depending on their investment goals and risk tolerance:

• Long-Term Holding: Many institutional investors and some retail investors may adopt a long-term holding strategy, based on the belief that Dermata Therapeutics, Inc. (DRMA) will generate significant value over time as its products advance through clinical trials and regulatory approval.
• Short-Term Trading: Hedge funds and some retail investors may engage in short-term trading, seeking to profit from fluctuations in Dermata Therapeutics, Inc. (DRMA)'s stock price driven by news events, clinical trial data releases, and market sentiment.
• Value Investing: Some investors may see Dermata Therapeutics, Inc. (DRMA) as undervalued based on its assets, pipeline potential, and future revenue projections, leading them to adopt a value investing approach.

A detailed breakdown of Dermata Therapeutics, Inc. (DRMA)'s investor composition can be gleaned from regulatory filings and financial news sources. These sources provide insights into major shareholders, institutional holdings, and insider transactions, offering a clearer picture of who is invested in the company and how their investment strategies may impact its stock performance.

Understanding the motivations and strategies of these diverse investor groups is essential for anyone looking to invest in Dermata Therapeutics, Inc. (DRMA) or seeking to understand the dynamics influencing its market behavior. For more in-depth information on Dermata Therapeutics, Inc. (DRMA), you can explore: Dermata Therapeutics, Inc. (DRMA): History, Ownership, Mission, How It Works & Makes Money.

Dermata Therapeutics, Inc. (DRMA) Institutional Ownership and Major Shareholders of Dermata Therapeutics, Inc. (DRMA)

Dermata Therapeutics, Inc. (DRMA) has a mix of institutional and individual investors. Understanding who these investors are and how their ownership has changed can provide insights into the company's stock performance and strategic direction. Here's a detailed look at the institutional ownership and major shareholders of Dermata Therapeutics, Inc. (DRMA):

Top Institutional Investors

As of late 2024 and early 2025, several institutional investors have reported their holdings in Dermata Therapeutics, Inc. (DRMA) to the Securities and Exchange Commission (SEC). These institutions hold a significant number of shares, reflecting their investment in the company. Key institutional investors include:

• Armistice Capital, LLC: Holding 27,200 shares as of December 31, 2024, valued at $19,828.
• UBS Group AG: Holding 13,874 shares as of December 31, 2024, valued at $10,114.
• Fidelity Concord Street Trust-Fidelity Extended Market Index Fund (FSMAX): Holding 6,580 shares as of February 28, 2025, valued at $4,798.
• Wells Fargo & Company: Holding 2,040 shares as of December 31, 2024, valued at $1,490.
• Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund (FCFMX): Holding 1,830 shares as of February 28, 2025, valued at $1,331.
• Tower Research Capital LLC (TRC): Holding 1,390 shares as of December 31, 2024, valued at $1,016.
• SBI Securities Co., Ltd.: Holding 1,000 shares as of December 31, 2024, valued at $728.
• Bank of America Corporation: Holding 16 shares as of December 31, 2024, valued at $11.

Changes in Ownership

Institutional ownership in Dermata Therapeutics, Inc. (DRMA) has seen some changes recently. According to Fintel, the institutional shares (long) have increased by 0.04 million shares, a 375.76% change in the most recent quarter. Some notable changes in holdings include:

• Armistice Capital, LLC: Increased shares to 276,422 as of February 14, 2025, a 48.45% change.
• Intracoastal Capital, LLC: Increased shares to 262,468 as of January 28, 2025, an 82.34% change.
• UBS Group AG: Increased its holdings significantly, with a change of 826.79% in shares.

Overall, institutional investors hold approximately 54,003 shares in Dermata Therapeutics, Inc. (DRMA).

Impact of Institutional Investors

The presence and activity of institutional investors can significantly influence a company's stock price and overall strategy. Here’s how these large investors can impact Dermata Therapeutics, Inc. (DRMA):

• Stock Price: Institutional buying can drive up the stock price, signaling confidence in the company's prospects. Conversely, selling by these investors can exert downward pressure on the stock. For instance, the share price of Dermata Therapeutics, Inc. (DRMA) on April 14, 2025, was $0.80, a significant decline of 98.82% from $67.50 on April 15, 2024.
• Company Strategy: Major shareholders, especially those holding more than 5% of the company, may actively pursue changes in business strategy. Their investment decisions and sentiments can influence corporate governance and strategic direction.
• Market Sentiment: The Fund Sentiment Score, which identifies companies with high levels of institutional accumulation, can reflect the overall market sentiment towards Dermata Therapeutics, Inc. (DRMA).

Major Individual Shareholders and Insiders

Besides institutional investors, individual insiders also hold substantial stakes in Dermata Therapeutics, Inc. (DRMA). These include:

• Proehl Investment Ventures LLC: Owns 2,905,544 shares, representing 53.50% of the company, valued at approximately $3.60 million.
• Gerald T. Proehl: Holds 800,610 shares, which accounts for 14.74% of the company.

Insider ownership is notably high, with insiders collectively holding 85.19% of the company's shares.

Additional Factors Influencing Ownership

Several other factors can provide a more comprehensive view of Dermata Therapeutics, Inc. (DRMA)’s investor profile:

• Activist Investors: Gerald T. Proehl increased his shares significantly, holding 804,098 shares as of April 7, 2025, marking a 245.06% change.
• Share Dilution: Shareholders have experienced substantial dilution in the past year, with total shares outstanding growing by 1123%.
• Financial Health: Despite challenges, Dermata Therapeutics, Inc. (DRMA) maintains a positive current ratio of 1.79 and holds more cash than debt, though its overall financial health score is fair at 1.77 out of 5.

Here is a summary of Dermata Therapeutics, Inc. (DRMA)'s major holders:

For more insights into Dermata Therapeutics, Inc. (DRMA), you might find this link helpful: Dermata Therapeutics, Inc. (DRMA): History, Ownership, Mission, How It Works & Makes Money

Dermata Therapeutics, Inc. (DRMA) Key Investors and Their Impact on [Company Name]

Understanding the investor profile of Dermata Therapeutics, Inc. (DRMA) is crucial for gauging market sentiment and potential stock movements. Key investors can exert considerable influence on a company's decisions and its stock performance through significant holdings and strategic moves.

While pinpointing every single investor and their exact impact is challenging due to the dynamic nature of stock ownership and reporting lags, we can analyze available data to identify notable trends and potential influencers.

Institutional investors often hold substantial shares in publicly traded companies like Dermata Therapeutics, Inc. (DRMA). These institutions include:

• Hedge funds
• Mutual funds
• Pension funds
• Insurance companies

These investors' activities, such as buying or selling large blocks of shares, can create significant price volatility and influence investor confidence. Monitoring their filings with the Securities and Exchange Commission (SEC), specifically Form 13F, provides insights into their holdings and recent transactions.

Activist investors may also play a role, especially if they believe the company's stock is undervalued or that strategic changes are needed. These investors often take significant positions and publicly advocate for changes in corporate governance or business strategy. Their involvement can sometimes lead to dramatic shifts in company direction and stock value.

Recent moves by key investors, such as increasing or decreasing their stakes, can signal confidence or concern about the company's future prospects. For example, a large purchase by a well-respected fund might encourage other investors, while a significant sell-off could trigger a decline in share price.

To get a deeper understanding of Dermata Therapeutics, Inc. (DRMA)'s financial standing, you might find this resource helpful: Breaking Down Dermata Therapeutics, Inc. (DRMA) Financial Health: Key Insights for Investors

While specific, real-time data on all Dermata Therapeutics, Inc. (DRMA) investors is not available, keeping an eye on SEC filings and financial news reports can provide valuable clues about who is investing and why. As of now, comprehensive details on specific investors and their recent moves require continuous monitoring of financial news and regulatory filings.

Dermata Therapeutics, Inc. (DRMA) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions is crucial for assessing the potential of Dermata Therapeutics, Inc. (DRMA). Here's a breakdown of the current investor landscape:

• Investor Sentiment: Currently, the sentiment leans towards a positive outlook. Analyst ratings as of April 18, 2025, indicate a 'Strong Buy' consensus.
• Analyst Ratings: Analysts have given Dermata Therapeutics a consensus rating of Strong Buy.
• Analyst Recommendations: 100% of analysts recommend a Strong Buy, with 0% recommending Buy, Holding, Selling, or Strong Sell.

Recent market reactions to Dermata Therapeutics have been significantly influenced by strategic announcements and progress in their clinical pipeline. For example, on March 27, 2025, the stock experienced a boost of 5.19% following positive news regarding their lead product candidate.

Here’s how the stock market has reacted to key developments:

• Patent Approval: The Australian Patent Office's approval of a patent application for Dermata's DMT410 positively impacted the stock.
• Phase 3 Trial Completion: Completion of the Phase 3 trial for XYNGARI, an acne treatment, has instilled optimism among investors, with plans to submit to the FDA.

However, it's important to note that Dermata Therapeutics has faced challenges. As of April 16, 2025, the stock hit a 52-week low at $0.70, reflecting an 83.63% erosion in stock value over the past year. This downturn is coupled with a delisting warning from Nasdaq due to non-compliance with minimum stockholders' equity requirements.

Despite these challenges, Dermata has taken steps to address its financial position:

• Private Placement: Secured $2.55 million through a private placement transaction.
• Warrant Exercises: Raised $6.2 million through the immediate exercise of outstanding warrants.

These funds are intended to support research and development, clinical trials, and general operations.

Here’s a summary of analyst perspectives and price targets:

• Consensus Price Target: The consensus price target from analysts is $6.00.
• Analyst Ratings: Wall Street analysts rate DRMA as Bullish on average.

Institutional ownership in Dermata Therapeutics is relatively low. As of December 31, 2024:

• % of Shares Held by Institutions: 0.84%
• % of Float Held by Institutions: 1.14%
• Number of Institutions Holding Shares: 6

The top institutional holders include:

Recent insider transactions show sales of shares, indicating a mixed sentiment from within the company. For example, on January 5, 2024, several insiders executed sales of their holdings.

Despite the challenges, Dermata's progress with XYNGARI and DMT410, along with recent financial maneuvers, suggest potential for future growth. Monitoring analyst ratings, market reactions, and company-specific developments remains crucial for investors.

To gain further insights into the financial health of Dermata Therapeutics, Inc. (DRMA), consider exploring this resource: Breaking Down Dermata Therapeutics, Inc. (DRMA) Financial Health: Key Insights for Investors